Insulin TDD Estimator
Estimates total daily dose (TDD) of insulin for new insulin starts. 50% basal, 50% bolus split. Adults: starting dose for a basal-bolus regimen (0.3 units/kg if frail, elderly or with renal impairment; 0.5 units/kg otherwise). Children: use a children's formulary and the paediatric diabetes team.
Score interpretation
Estimated total daily insulin dose. Split: Basal = TDD × 50%; Bolus per meal = TDD × 17% (÷ 3 meals).
→ This is a starting estimate ONLY. Titrate based on glucose monitoring. Consult diabetes team. Provide hypoglycaemia education. Prescribe glucose gel or Glucagon kit.
Interpretation bands for the Insulin TDD. Apply clinical judgement and local guidance.
References
- NICE NG28. Type 2 diabetes in adults: management. 2022.
- Joint British Diabetes Societies (JBDS). Management of Hyperglycaemia in Adults in the Inpatient Setting. 2021.
- Umpierrez GE et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). Diabetes Care. 2007;30:2181–2186.
Related
Curated clinical cross-links plus same-class fallbacks.
- Insulin Glargine · Long-Acting Insulin Analogue (Basal)
- Insulin Aspart · Rapid-Acting Insulin Analogue (Bolus)
- Tirzepatide · Dual GIP/GLP-1 Receptor Agonist — Type 2 Diabetes / Obesity
- Isophane (NPH) insulin · Intermediate-acting insulin
- Dopamine (ICU — Vasopressor/Inotrope) · Catecholamine (Dose-Dependent Vasopressor/Inotrope)
- Insulin (IV Infusion — ICU Glucose Control) · Insulin — ICU Glucose Management
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Adult Hypoglycaemia (Treated Diabetes) · JBDS-IP (2023): Hospital Management of Hypoglycaemia
- Adrenal Crisis · Society for Endocrinology Emergency Guidance (2024)
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.